.png){kind=small}
Next-Generation Sequencing for Cancer
5 Testing Strengths
Feasible Alternatives to Traditional Biopsies
Guardant360® CDx is a liquid biopsy test that uses next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) in blood samples. This test provides oncologists with valuable genomic information, enabling them to match advanced solid tumor patients with appropriate targeted therapies within 7 days.
１
Comprehensive blood test approved by the US FDA and CE in the EU for matching cancer treatments
３
Reports available within as fast as 7 days
５
Simultaneously tests 74-739 cancer-related genes and high microsatellite instability
(MSI-high)
２
In cases where tumor tissue is difficult to obtain safely, feasible alternatives to traditional tissue biopsies
４
Effectively identifies useful biomarkers that are missed in tissue biopsies
6
Compared to early-extracted tumor tissue, liquid biopsies can provide the most up-to-date information on cancer gene mutations
７
Capable of detecting all solid tumor cancers
Applicable to
Testing Process
Existing liquid biopsy subsidy program for public hospital patients
Next-generation sequencing liquid biopsy genetic testing program for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide. Early detection and diagnosis are crucial for improving treatment success rates and patient survival outcomes.
Liquid biopsy genetic testing analyzes circulating tumor DNA (ctDNA) released during the division of cancer cells in blood or other body fluids to check for gene mutations. This method has an accuracy rate of over 70-80% and can guide the selection of targeted therapies.
-
Hong Kong residents with a valid Hong Kong Identity Card
-
Patients of hospitals under the Hospital Authority
-
Confirmation from a Hospital Authority doctor for the need for lung cancer liquid biopsy genetic testing
-
Diagnosed with non-small cell lung cancer
-
Negative results for EGFR ex19del, EGFR L858R, EGFR T790M, and ALK gene tests